Edwards Lifesciences Corp reports $1.65 billion revenue for quarter ended March 31, 2026
Edwards Lifesciences Corp reported revenue of $1.65 billion for the quarter ended March 31, 2026.
For the same period it posted net income of $380.7 million, or $0.66 per diluted share.
That is a net margin of 23.1%.
On Sanad's AAOIFI Standard 21 screen, Edwards Lifesciences Corp is currently compliant: interest-bearing debt is 1% of market capitalisation (limit 30%), and impure income is 2.8% of revenue (limit 5%).
Is Edwards Lifesciences Corp halal?
See the full AAOIFI screening of Edwards Lifesciences Corp
See the full AAOIFI screening of Edwards Lifesciences Corp
Source: 10-Q filed with the U.S. Securities and Exchange Commission on May 6, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.